openPR Logo
Press release

Generation of Engineered Human Myocardium using myriamed myrPlates

10-30-2020 09:36 AM CET | Health & Medicine

Press release from: myriamed GmbH

Generation of Engineered Human Myocardium using myriamed myrPlates

Generation of Engineered Human Myocardium using myriamed myrPlates

In STAR Protocols Tibury et al. describe a robust method for the generation of engineered human myocardium (EHM) from pluripotent stem cells (PSCs) in 48 well myriamed myrPlates under defined, serum-free conditions (DOI: 10.1016/j.xpro.2020.100032).

By parallel culture of up to 48 EHM in one myrPlate, contractile heart muscle can be obtained to serve numerous applications, such as drug screening and disease modelling, which are also offered by myriamed.

The described protocol has been successfully applied to human embryonic stem cell- and induced PSC-derived cardiomyocytes, subtype-specific, i.e., atrial and ventricular, and commercially available cardiomyocyte preparations (e.g. myrCell Cardio).

To read the protocol please visit:
https://bit.ly/myrPlateEHMprotocol

To learn more about myrPlates and myriamed’s other products please contact us on:
https://bit.ly/myriamed_contact

myriamed GmbH
Rudolf-Wissell-Str. 28a
37079 Göttingen
Tel.: +49 551 28878-170
Email: info@myriamed.com
Web: www.myriamed.com

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generation of Engineered Human Myocardium using myriamed myrPlates here

News-ID: 2176933 • Views: 441

More Releases from myriamed GmbH

myriamed has joined Science Exchange
Science Exchange, the leading SaaS-enabled marketplace platform for outsourced R&D services, has partnered with myriamed. Visit myriamed’s profile to inquire about our services or request a quote. There are no additional contracts required if you request on Science Exchange and you can order immediately. Please visit our profile here: http://bit.ly/myriamed_Science_Exchange About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and
myriamed is now a member of the Network for Pharma Solutions
We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in
Helping to accelerate the development of novel drugs against Covid-19 disease
Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021. Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the
myriamed’s myrPlates are now also available from ZAGENO
We are proud to announce that myriamed’s myrPlates are now also available in the ZAGENO life science, e-commerce marketplace. myrPlates can be used for the generation of engineered human tissues. By parallel culture of up to 48 tissues in one myrPlate, e.g. contractile heart muscles or skeletal muscles can be obtained to serve numerous applications, such as drug screening and disease modelling. About myriamed: myriamed has unique expertise in research and development

All 5 Releases


More Releases for Generation

Digital Services for Lead Generation, Lead Generation Platforms: Ken Research
The Lead generation is the practice of gaining fresh leads for your business. It is cultivating the interest of a person in your product or service so much that they distribute you with their contact specifics. It is the start of the technique which leads to a prospective customer turning into a purchaser. And then perchance buying from your business. Your business should then be nurturing such leads that you
Next Generation Sequencing Market
According to IMARC Group’s latest report, titled “Next-Generation Sequencing (NGS) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the global next generation sequencing (NGS) market is expanding at double digit growth rate and is expected to grow at a CAGR of 17% during 2020-2025. Next-generation sequencing refers to the process of determining the sequence of nucleotides in DNA. It involves various procedures, such as sequencing by synthesis (SBS),
Global Lead Generation Websites, LinkedIn B2B Lead Generation: Ken Research
The Business proprietors are always looking for the detailed lead generating ideas for the grocery stores, gyms, e-commerce sites, and numerous others. In reality, though, most of the lead generation strategies function well for all the practices of businesses, exclusively when we are talking regarding the B2C space. The B2C and B2B lead generation services of the Ken Research would upkeep you to intensification the sales, progress the market share and
Generation Outcast Clothing
Outcast Clothing was founded in late 2014 by a young power couple who wanted to make a difference in the world of online shopping. From the day Outcast Clothing launched, the young couple packed every parcel by hand from their one bedroom apartment. Each parcel represented an important, growing relationship with a customer. Unit 3 -4 Revelation Close Tighes Hill, NSW 2297 Today, Outcast Clothing has grown to become a go to online
Next-generation Sequencing Market
Next-generation sequencing or high throughput sequencing are advanced DNA sequencing technologies, including Illumina (Solexa) sequencing, Roche 454 sequencing, and Ion torrent: Proton/ PGM sequencing, SOLiD sequencing. Next-generation sequencing technologies have a number of advantages such as high speed, flexibility, high throughput, and reduced sequencing cost. Next-generation sequencing has ability to produce terabytes of nucleotide sequence data in a lone sequencing procedure. The NGS technology is developing at a rapid rate,
Next Generation Network expanded
MEDIA BROADCAST connects its NGN platform with international telecommunications network node in Frankfurt Bonn, 25 March 2009 – MEDIA BROADCAST has now connected its BROADCAST NGN (Next Generation Network) with the international telecommunications network node from ancotel, operator of the biggest data and telecommunications node in Europe. The NGN, which was conceived by MEDIA BROADCAST as an all-in-one network, is available throughout Germany and provides uncompromising service to radio,